Skip to main content

Argonaut Shareholders Approve Purchase by Biotage of Portions of Company

NEW YORK, June 2 (GenomeWeb News) - A majority of Argonaut's shareholders have approved the acquisition of parts of the company by Biotage, according to a statement the companies released today.


Those portions -- Argonaut's reagents and process instruments business -- will officially be part of Biotage on June 3. Biotage will pay 155 MSEK ($20.9 million) for the components.


The acquisition is aimed at strengthening Biotage's offering in medicinal chemistry, according to Jeff Bork, president and CEO.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.